Successful pregnancy and delivery in two patients on maintenance hemodialysis. Usefulness of .ALPHA.-human atrial natriuretic peptide in determining dry weight.

Takayasu Horiguchi, Isao Ishikawa, Keiichi Takada, Michihiro Nakamura, Keita Tateishi, Hiroshi Ishii, T Nakazawa, Hirohisa Kitada, Takehisa Yuri, Akira Shinoda, Katsuhiko Yoshida, Jirou Tanno, Souryu KuwaharaJournal of Japanese Society for Dialysis Therapy 1993 · DOI

Abstract

Managing pregnancy in patients with end-stage renal disease (ESRD) on maintenance hemodialysis presents significant clinical challenges, particularly in determining the optimal "dry weight" (DW). This report details two successful pregnancies where plasma α-human atrial natriuretic peptide (α-hANP) was utilized as a biochemical marker for fluid management. Both patients, aged 30 and 31, were maintained on recombinant erythropoietin (rEPO) to sustain hematocrit levels above 30%. By monitoring α-hANP levels and adjusting dialysis targets accordingly, both pregnancies reached 34 weeks, resulting in the delivery of healthy infants via Caesarean section.

Introduction

Pregnancy in dialysis patients is historically rare and associated with high risks of maternal hypertension, severe anemia, and fetal growth restriction. A primary hurdle is the accurate determination of dry weight—the patient's weight at the end of a dialysis session when excess fluid is removed. Normal pregnancy-related weight gain (fetus, placenta, amniotic fluid) often masks pathological fluid retention. Over-aggressive fluid removal can lead to maternal hypotension and placental insufficiency, while under-removal risks heart failure and pulmonary edema. This study evaluates the utility of α-hANP as an objective physiological guide for fluid management in these complex cases.

Clinical Cases and Methods

The study follows two patients at Kanazawa Medical University:

  • Case 1: A 30-year-old woman on dialysis for 6 years.
  • Case 2: A 31-year-old woman who returned to dialysis after a failed renal transplant.

Both patients received rEPO to maintain stable hematocrit levels, a critical factor for fetal oxygenation. The innovative aspect of their care was the longitudinal measurement of plasma α-hANP. This peptide is secreted by the cardiac atria in response to volume-induced stretch, making it a direct proxy for cardiac preload. The clinical team aimed for an α-hANP target range of 50–70 pg/ml to guide fluid removal. Dialysis frequency was increased to up to four times per week, and tocolytic therapy was administered to prevent premature labor.

Historical Context and Data

To contextualize these outcomes, the authors reviewed 34 previously reported cases of pregnancy on dialysis in Japan up to 1991. This historical data highlights the variability in gestational age at delivery and birth weights, underscoring the high-risk nature of these pregnancies.

Table 1: Summary of 34 historical cases of pregnancy on maintenance hemodialysis in Japan (1977-1991).

Key Insights: α-hANP as a "Volume Compass"

The use of α-hANP provided a more objective metric than traditional physical examinations or chest X-rays. In Case 2, monitoring revealed a significant spike in α-hANP levels (exceeding 100 pg/ml), which served as an early warning sign of fluid overload (polyhydramnios) before the onset of severe clinical symptoms. This allowed for preemptive adjustments to the dry weight target.

Figure 1: Clinical course of Case 2, showing the relationship between blood pressure (BP), BUN, Creatinine (Cr), Hematocrit (Ht), α-hANP, and body weight (BW) throughout the pregnancy. Note the α-hANP spike around week 24.

Furthermore, the team observed that maintaining α-hANP at levels slightly lower than those typically seen in healthy pregnant women helped mitigate the hypertensive complications often seen in dialysis-dependent pregnancies. The synergy between precise fluid management and rEPO therapy was vital; rEPO maintained stable hematocrit levels without the need for frequent blood transfusions.

Results and Outcomes

Both patients successfully delivered via Caesarean section at 34 weeks:

  • Case 1: Male infant, 1,613g, Apgar score 9.
  • Case 2: Male infant, 1,713g, Apgar score 8.

Despite low birth weights due to prematurity, both infants were healthy and survived. Throughout the pregnancies, Blood Urea Nitrogen (BUN) was kept below 70 mg/dl and Creatinine (Cr) remained around 6–7 mg/dl, meeting recommended thresholds to minimize fetal toxicity.

Conclusion

While limited by a small sample size, these cases demonstrate that α-hANP monitoring is a valuable tool for managing the "moving target" of dry weight in pregnant dialysis patients. By providing a physiological marker for cardiac preload, α-hANP allows for safer, more precise fluid management, reducing the risks of both volume overload and placental hypoperfusion. This approach, combined with modern anemia management via rEPO, significantly improves the prospects for successful pregnancy outcomes in ESRD patients.

Summary updated

Abstract

透析技術の進歩ならびにエリスロポイエチン (EPO) の使用により, 透析患者の妊娠・分娩の成功例が報告されている. 当院においても2例の妊娠・分娩を経験し, ドライウェイト (DW) 設定の指標としてα-hANPの測定を行い有用と考えられたので報告する. 症例1は30歳, 透析歴6年で妊娠 (ss) 10週に当科入院. ss 34週, 帝王切開にて1,613gの男児を分娩した. 症例2は31歳, 透析2年目に腎移植, 3年後に透析再導入となり1年6か月後にss 17週と診断. ss 34週, 帝王切開にて1,713gの男児を分娩した. 2症例とも妊娠前よりEPOを使用しており, 妊娠中はEPOにてHt 30%以上に維持でき, 更に, 体重管理の指標の一つとしてα-hANPの測定を行いより少ないriskで妊娠の継続, 分娩が可能であった.
BibTeX
@article{horiguchi1993successful,
  author = {Takayasu Horiguchi and Isao Ishikawa and Keiichi Takada and Michihiro Nakamura and Keita Tateishi and Hiroshi Ishii and T Nakazawa and Hirohisa Kitada and Takehisa Yuri and Akira Shinoda and Katsuhiko Yoshida and Jirou Tanno and Souryu Kuwahara},
  title = {{Successful pregnancy and delivery in two patients on maintenance hemodialysis. Usefulness of .ALPHA.-human atrial natriuretic peptide in determining dry weight.}},
  journal = {Journal of Japanese Society for Dialysis Therapy},
  year = {1993},
  doi = {10.4009/jsdt1985.26.1225},
}
Figure